# Trade Mark Journal No.2025/044 31 October 2025

## WO0000001881489 (5,42,44)

Office of origin: United States of America

Date of International Registration:18 August 2025
Date of designation in the UK: 18 August 2025

International priority date claimed: 24 April 2025 (United States of America) (99152854)

Class 5
  Pharmaceuticals for the treatment of rare genetic diseases; pharmaceuticals for the treatment of musculo-skeletal disorders; pharmaceuticals for the treatment of skeletal dysplasia.
Class 42
  Research and development of drugs in the fields of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; scientific research for medical purposes in the fields of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; clinical research in the fields of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; scientific research and development of pharmaceuticals for the treatment of rare diseases, musculo-skeletal disorders, and skeletal dysplasia.
Class 44
  Providing medical information; providing medical information in the field of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; providing medical information via a web site; providing information in the field of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; providing information in the field of pharmaceuticals via a web site.

Tyra Biosciences, Inc.

Representative: Kevin M. Bovard Baker & Hostetler LLP, 1735 Market Street, Suite 3300, Philadelphia PA 19103, UNITED STATES OF AMERICA